Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1

Interventions

Imiquimod 2relugolix 1nilutamide 1histrelin 1enzalutamide 1bicalutamide 1apalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Triptorelin Pamoate 1Thioctic Acid 1Prednisone 1Picibanil 1Methylprednisolone 1Leuprolide 1Goserelin 1Flutamide 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × FED × Picibanil × Clear all
NCT00010452 2015-03-25

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

FDA Office of Orphan Products Development

Phase 2/3 Completed
150 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon âš¡